Chemical Makers Sue Over Rule to Rid Water of ‘Forever Chemicals’

Unsurprisingly, in the wake of new PFAS regulations, some in the industry are pushing back against the tough new treatment standards.

Great story in the New York Times on the topic: https://www.nytimes.com/2024/06/10/climate/pfas-forever-chemicals-lawsuit.html

On June 10, the New York Times reported a lawsuit by several chemical and manufacturing groups against the federal government over the per- and polyfluoroalkyl (PFAS) “Forever Chemical” drinking water standards announced by the EPA two months prior. The groups claim that the new regulations exceed the government’s authority under the Safe Drinking Water Act by requiring municipal water systems across the country to filter out some of the synthetic chemicals to near non-detectable levels.  

While the EPA has said that the new standard will prevent serious illness and even death for thousands of people, these groups, along with some utilities, have brought challenges against the standard, questioning the science behind it and citing the potential cost of filtering out the chemicals. The American Water Works Association and the Association of Metropolitan Water Agencies believe the EPA have “significantly underestimated” the cost for treatment plants to meet the new standards, with the EPA estimating about $1.5 billion annually to comply and utilities claiming it could cost twice that amount.  

Ahead of the filing, Brenda Mallory, chair of the White House’s Council on Environmental Quality, in a public address defended the administration’s standards, stating: “Everyone should be able to turn on the tap and know that the glass of water they fill is safe to drink”. EPA officials also stated that the standard was based on the best available science and designed to be, “robust enough to withstand litigation”.
 

BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract

USAF work now amounts to over $100,000 in revenue per month.

Westminster, CA – June 20, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a subcontract to provide air quality services to two Arizona U.S. Air Force bases for up to four years, with expected annual revenue of approximately $812,000.

The news comes on the heels of a similar recently announced contract award to serve three Air Force bases in New Mexico, which has a potential annual average revenue of $650,000. BioLargo’s work at the Arizona bases consists primarily of the air quality regulatory compliance portion of a Fence-to-Fence (F2F) support contract through prime contractor HLTLI Joint Venture, LLC, a joint venture between HL Environmental Services and TLI Solutions.

The four-year prime contract secures pricing for F2F services over the term of the contract but does not guarantee continuation of the contract over that duration. In the past, BioLargo’s engineers have continued providing services through the duration of the prime contract. In total, BioLargo Engineering’s work at Air Force bases now amounts to over $100,000 of revenue per month.

BioLargo Engineering, Science & Technologies President Randall Moore commented, “We are pleased and honored to continue providing vital engineering services to the United States Air Force and supporting their active mission and environmental compliance needs. These new contracts will provide for over $100,000 a month of ongoing fixed revenues while we continue to expand our abilities to support new opportunities.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products

Westminster, CA – June 12, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. (“Clyra”) has selected Keystone Industries, a global manufacturer of medical, dental and cosmetic products with distribution partners in more than 70 countries, to support manufacturing of its medical products. The relationship focuses on the build-out of scaled manufacturing capacity for Clyra’s FDA 510(k) cleared Bioclynse surgical wound irrigation solution. Clyra and Keystone have been and continue to make significant investments to support the launch of Bioclynse.

Bioclynse is Clyra’s FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:

• Non-cytotoxic, non-sensitizing, no damage to tissue
• No rinse-out required
• Non-staining
• Sustained multi-day efficacy
• Effective against biofilms

Cary Robinson, President and CEO of Keystone Industries, said, “We are excited to support Clyra Medical Technologies to bring Bioclynse to the market. Keystone has a century of experience in developing and manufacturing medical device, OTC and pharmaceutical products. We have committed a significant investment in our infrastructure to support the manufacturing of innovative products like Clyra’s Bioclynse and can readily provide the needed support to scale up production rapidly.”

Steve Harrison, President of Clyra Medical Technologies, commented, “We are continuing to work hard and spend money to support the scaled roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing partner willing to invest significant money in new equipment and dedicated space was critical to these efforts. We look forward to a long and mutually prosperous relationship with Keystone.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Keystone Industries, Inc.

Keystone Industries is a market leader with over 100 years experience in developing cosmetic, medical device, OTC and pharmaceutical products. The company operates through a diverse network of over 800 U.S. and international distribution partners in more than 70 countries. Keystone maintains FDA licensing, ISO 13485 (medical device) and 22716 certifications, as well as GMP certification and international product registrations. Keystone’s commitment to innovation and quality ensures that the company consistently exceed the evolving needs of their customers. See our website at www.keystoneindustries.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion

Westminster, CA – June 11, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first Cellinity^TM “Liquid Sodium” prototype battery cells. Visit www.BioLargoEnergy.com to learn more.

Cellinity is BioLargo’s next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery – rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry. These newly manufactured Cellinity prototype cells will now be tested and validated for the energy storage and transfer performance claims that were generated in the technology’s early-stage research and development by its original inventors:

• Far greater safety – no runaway fires, no risk of explosion;
• Extremely long-lasting – no performance decrease over thousands of cycles;
• No self-discharging, no out-gassing, and no parasitic load for cooling;
• High energy density – more energy per unit of weight than lithium batteries;
• All materials can be sourced within North America without the need for rare-earth elements.

“Successfully manufacturing our first battery cells is a pivotal moment in the journey of our battery technology,” said Dennis P. Calvert, President and CEO of BioLargo. “The testing and validation of these cells will allow us make claims about the capacity, charge/discharge rate, and other performance characteristics that we believe differentiate our batteries in the marketplace. After testing and validation, we will manufacture full-scale prototype Cellinity battery modules in 25- and 45-kilowatt hour capacities for further testing and validation.”

He continued, “In parallel to our ongoing development of the Cellinity battery, we’re exploring various financing options that ensure we get paid for and are in control of the engineering and construction of manufacturing facilities. Although initial discussions have taken place, we have no agreements in place. We believe a licensing and partnership model to be a better alternative to self-financed and self-operated manufacturing facilities competing with the likes of Tesla, and well suited for community-based manufacturing partners focused on underserved communities that are in special need of reliable renewable energy. Our target projects will add value to communities, develop workforces, stimulate economic development, promote grid stability and enable the development and expansion of micro-grids around the world. We will fundamentally enable and enhance the adoption of renewable energy.”

Mr. Calvert finished by saying, “The world needs a reliable, safe and eco-friendly alternative to lithium batteries, and we believe our Cellinity battery will meet these needs.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project

Westminster, CA – June 7, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a contract to provide air quality services to three New Mexico U.S. Air Force (USAF) bases for up to five years, with a potential annual average revenue of $650,000.

The new contract is in addition to ongoing environmental support work at six Air Force bases and is the company’s largest dollar-value Air Force contract to date. These contracts provide regularly monthly flat fee revenue to the company over the life of the contract, which the Air Force may renew each year. BioLargo’s work at the New Mexico bases includes air quality regulatory compliance. Bhate Environmental Associates is the prime contractor with the Air Force under the Fence-to-Fence (F2F) support contract.

BioLargo Engineering, Science & Technologies President Randall Moore commented, “Our team has served Air Force bases with fence-to-fence air quality compliance services for years, but this is the largest such contract we’ve secured to-date. Larger, long-term contracts such as this one are crucial to our strategy of securing steady, reliable income from external clients. This empowers us to focus on commercializing BioLargo’s innovative cleantech technologies, including advancements in water treatment, energy storage, and air quality solutions.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Bhate Environmental Associates, Inc.

Bhate Environmental Associates, Inc. (Bhate) provides a diverse range of technical services in the environmental and infrastructure markets to the federal government and private industry. Headquartered in Birmingham, Alabama, Bhate’s reach is both national and global. At Bhate, we value high standards of safety, professionalism, ethics, and service to our clients. We foster a collaborative environment that encourages innovative ideas while providing challenges and rewards for our dedicated staff. Through our team’s Responsiveness, Integrity, and Teamwork, Bhate delivers professional, quality, cost-effective, and on-time results to our clients. See their website at www.Bhate.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024

Westminster, CA – May 14, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that the company generated $481,000 operating cash flow with record quarterly revenues of $4,760,000 for the three months ended March 31, 2024. The company filed its quarterly report on Form 10-Q with full financial results, available at www.biolargo.com/sec-filings.  

BioLargo will hold an investor webcast on Tuesday May 14, 2024, at 2:30 pm Pacific Time, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/50622   

BioLargo’s President and CEO Dennis P. Calvert discussed the results of the quarter, “We’ve had several years in a row of exceptional revenue growth, and as a result generated positive cashflow from operations this past quarter. Our goal, of course, is positive net income, and results like these bring us closer to achieving that goal.”

He continued, “BioLargo is executing on a winning formula: a team of highly qualified people dedicated to inventing, proving, and partnering to capitalize on a diversified portfolio of transformative technologies with the potential to create real change in the world.”

Financial highlights from the first quarter of 2024:

• Companywide revenue for the three months ended March 31, 2024, grew to $4,760,000, a 9% increase over the fourth quarter of 2023 and a 28% increase over the first quarter of 2023.
• The company generated positive cash from operating activities (cashflow) of $481,000, compared with negative $2,000 in the fourth quarter of 2023.
• The company’s net stockholder’s equity increased from $4.2 million to $5.1 million.
• Net loss was $775,000, a 32% decrease compared to the previous quarter and a 57% increase compared to the same period of 2023. Net loss included $623,000 in non-cash equity compensation expenses.

Business highlights from the first quarter of 2024:

• Launched water equipment subsidiary to capitalize on opportunities in PFAS and water treatment.
• Appointed key industry leaders to board of water equipment subsidiary: Sally Gutierrez, former U.S. EPA Senior Advisor for Water; Jeffrey Kightlinger, recognized water industry leader; and Larry Dick, former Vice Chairman of the board of Metropolitan Water District of Orange County.
• The U.S. EPA finalized two important sets of regulations on PFAS that will influence the growth of the PFAS treatment market and may disproportionately favor our PFAS treatment technology because of its high efficacy against all types of PFAS and its low rate of production of solid PFAS-laden waste as a treatment byproduct.
• Clyra is making substantial investments for scaled-up distribution of its Bioclynse line of products and contracting with third parties for FDA-compliant product manufacturing.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Q1 2024 Earnings Results Webcast and Conference Call on Tuesday, May 14, 2024 - 5:30 PM Eastern Time

WESTMINSTER, CA /  May 10, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced it will host an investor webcast and conference call on Tuesday, May 14, 2024, at 2:30 pm Pacific / 5:30 pm Eastern. The event, which will be open to the public, will be held to review the company's financial results for the three months ending March 31, 2024, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/50622

Teleconference Domestic: 877-545-0523

Teleconference International: 973-528-0016

Participant Access Code: 447613

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Sunday, July 14, 2024

Teleconference Replay Expiration: Tuesday, May 28, 2024

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 50622

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo's website at www.biolargo.com/investor-relations.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.